ClinicalTrials.Veeva
Menu

Find clinical trials for Adenocarcinoma in Montréal, QC

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Carcinoma
Cancer
Pancreatic Cancer
Colorectal Cancer
Stomach Cancer
Esophageal Cancer
Non-Small-Cell Lung Carcinoma

Adenocarcinoma trials near Montréal, QC, CAN:

A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015) (TroFuse-015)

(TPC) in participants with advanced/metastatic gastroesophageal adenocarcinoma. The primary hypothesis of this study is sacituzumab tirumote...

Enrolling
Gastroesophageal Cancer
Drug: Rescue medication
Drug: Supportive care measures

Phase 3

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Montréal, Quebec, Canada and 165 other locations

Status recently updated

A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma

resectable gastric, gastroesophageal junction (GEJ), or esophageal adenocarcinoma who have not received previous treatment for the disease....

Not yet enrolling
Enrolling
Gastroesophageal Adenocarcinoma
Drug: Rilvegostomig
Drug: 5-Fluorouracil (5-FU)

Phase 2

AstraZeneca
AstraZeneca

Montréal, Quebec, Canada and 56 other locations

Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma

This study is being done to answer the following question:Can the chance of gastroesophageal cancer growing or spreading be lowered by adding a drug...

Enrolling
Gastroesophageal Adenocarcinoma
Drug: Zanidatamab
Drug: Paclitaxel

Phase 2

Canadian Cancer Trials Group

Montreal, Quebec, Canada and 17 other locations

A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body (STAR-221)

first-line treatment of participants with locally advanced unresectable or metastatic gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma...

Active, not recruiting
Advanced Upper Gastrointestinal Tract Adenocarcinoma
Drug: Domvanalimab
Drug: Zimberelimab

Phase 3

Arcus Biosciences
Arcus Biosciences

Montreal, Canada and 210 other locations

A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features (TROPION-Lung12)

after complete surgical resection (R0) in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive, as determined by the Sponso...

Enrolling
Non-small Cell Lung Cancer
Drug: Pemetrexed
Drug: Rilvegostomig

Phase 3

AstraZeneca
AstraZeneca

Montreal, Quebec, Canada and 217 other locations

Locations recently updated

A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

in participants with untreated metastatic Pancreatic Ductal Adenocarcinoma (PDAC) with homozygous methylthioadenosine phosphorylase (MTAP) d...

Begins enrollment in 3 months
Pancreatic Ductal Adenocarcinoma
Drug: BMS-986504
Drug: Placebo

Phase 2, Phase 3

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Montreal, Quebec, Canada and 258 other locations

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

and safety of AZD0901 compared to Investigator's choice of therapy as 2L+ treatment for participants with advanced or metastatic gastric or GEJ adenocarcinoma...

Enrolling
Gastroesophageal Junction Cancer
Gastric Cancer
Drug: Docetaxel
Drug: Irinotecan

Phase 3

AstraZeneca
AstraZeneca

Montreal, Quebec, Canada and 186 other locations

A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC (IMCODE003)

mFOLFIRINOX alone in participants with resected pancreatic ductal adenocarcinoma (PDAC) who have not received prior systemic anti-cancer tre...

Enrolling
Adenocarcinoma, Pancreatic Ductal
Drug: mFOLFIRINOX
Drug: Autogene cevumeran

Phase 2

Genentech
Genentech

Montreal, Quebec, Canada and 84 other locations

A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer. (Spotlight)

Zolbetuximab is being studied in people with cancer in and around the stomach or where the food pipe (esophagus) joins the stomach, called gastroesop...

Active, not recruiting
Metastatic Gastric Adenocarcinoma or Cancer
Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer
Drug: folinic acid
Drug: zolbetuximab

Phase 3

Astellas
Astellas

Montreal, Quebec, Canada and 219 other locations

Alpha Radiation Emitters Device for the Treatment of Pancreatic Cancer Emitters With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer

This is a multi-center clinical study enrolling up to 30 participants (15 patients in each cohort). The primary objective of the study is to evaluate...

Enrolling
Pancreatic Adenocarcinoma
Metastatic Pancreatic Cancer
Device: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
Alpha Tau Medical

Montréal, Quebec, Canada and 15 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2025 Veeva Systems